Cargando…
Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy
BACKGROUND: Diabetic retinopathy (DR), a microvascular complication of diabetes, is the leading cause of visual impairment in people aged 20–65 years and can go undetected until vision is irreversibly lost. There is a need for treatments for non-proliferative diabetic retinopathy (NPDR) which, in co...
Autores principales: | Boyer, David S., Rippmann, Joerg F., Ehrlich, Michael S., Bakker, Remko A., Chong, Victor, Nguyen, Quan Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042903/ https://www.ncbi.nlm.nih.gov/pubmed/33845913 http://dx.doi.org/10.1186/s40942-021-00288-7 |
Ejemplares similares
-
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
por: Newsome, Philip N., et al.
Publicado: (2023) -
Implication for Functions of the Ectopic Adipocyte Copper Amine Oxidase (AOC3) from Purified Enzyme and Cell-Based Kinetic Studies
por: Shen, Sam H., et al.
Publicado: (2012) -
Zinc-α2-glycoprotein as an inhibitor of amine oxidase copper-containing 3
por: Romauch, Matthias
Publicado: (2020) -
Human Copper-Containing Amine Oxidases in Drug Design and Development
por: Vakal, Serhii, et al.
Publicado: (2020) -
Increased atherosclerotic plaque in AOC3 knock-out in ApoE(−/−) mice and characterization of AOC3 in atherosclerotic human coronary arteries
por: Filip, Anna, et al.
Publicado: (2022)